Allergic rhinoconjunctivitis (ARC) is one of the commonest chronic diseases worldwide with increasing prevalence (1). Allergen Immunotherapy (AIT) has been thoroughly established as the only disease-modifying treatment option in patients with IgE-mediated allergic diseases such as AR with/without concomitant allergic asthma (2) (3).

中文翻译：

---

R1：过敏性鼻结膜炎的过敏原免疫疗法算法

过敏性鼻结膜炎 (ARC) 是全球最常见的慢性病之一，其患病率不断增加 (1)。过敏原免疫疗法 (AIT) 已被彻底确定为 IgE 介导的过敏性疾病（如 AR 伴/不伴过敏性哮喘）患者唯一的疾病缓解治疗选择 (2) (3)。